ATE295376T1 - Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung - Google Patents

Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung

Info

Publication number
ATE295376T1
ATE295376T1 AT99941314T AT99941314T ATE295376T1 AT E295376 T1 ATE295376 T1 AT E295376T1 AT 99941314 T AT99941314 T AT 99941314T AT 99941314 T AT99941314 T AT 99941314T AT E295376 T1 ATE295376 T1 AT E295376T1
Authority
AT
Austria
Prior art keywords
sub
receptor
csf
cytokine
binding
Prior art date
Application number
AT99941314T
Other languages
English (en)
Inventor
Angel Lopez
Andrea Richard D
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Application granted granted Critical
Publication of ATE295376T1 publication Critical patent/ATE295376T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99941314T 1998-08-13 1999-08-13 Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung ATE295376T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP5251A AUPP525198A0 (en) 1998-08-13 1998-08-13 Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
PCT/AU1999/000659 WO2000009561A1 (en) 1998-08-13 1999-08-13 Monoclonal antibody inhibitor of gm-csf, il-3, il-5 and other cytokines, and uses thereof

Publications (1)

Publication Number Publication Date
ATE295376T1 true ATE295376T1 (de) 2005-05-15

Family

ID=3809483

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99941314T ATE295376T1 (de) 1998-08-13 1999-08-13 Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung

Country Status (6)

Country Link
US (2) US6720155B1 (de)
EP (1) EP1105426B1 (de)
AT (1) ATE295376T1 (de)
AU (1) AUPP525198A0 (de)
DE (1) DE69925279T2 (de)
WO (1) WO2000009561A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
JP2002541061A (ja) 1999-02-08 2002-12-03 メドベット・サイエンス・プロプライエタリー・リミテッド サイトカイン結合ドメイン
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US8062637B2 (en) 2000-05-08 2011-11-22 Morphosys Ag Methods of ameliorating inflammatory disease using an uPA antagonist
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
ES2527428T3 (es) * 2005-05-18 2015-01-23 Morphosys Ag Anticuerpos anti-GM-CSF y usos de los mismos
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
WO2009006688A1 (en) * 2007-07-11 2009-01-15 Medvet Science Pty Ltd Regulating il-4 and il- 13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
GB0723179D0 (en) * 2007-11-27 2008-01-02 Immunovia Ab Diagnostic methods and arrays for use in the same
EP2193790A1 (de) * 2008-12-04 2010-06-09 Klinikum der Universität Regensburg IL-3-Inhibitoren zur Verwendung bei der Behandlung von rheumatoider Arthritis im Frühstadium
CN102256621B (zh) 2008-12-22 2017-12-12 墨尔本大学 疼痛治疗
US9243061B2 (en) 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
US20100209341A1 (en) * 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
EP2885002A4 (de) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten
WO2014092804A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
EP3204018B1 (de) 2014-10-07 2021-08-25 Immunomedics, Inc. Neoadjuvante verwendung von antikörper-wirkstoff-konjugaten
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
SI3316885T1 (sl) 2015-07-01 2021-09-30 Immunomedics, Inc. Imunokonjugati protitelo-SN-38 z linkerjem CL2A
WO2017027898A1 (en) * 2015-08-18 2017-02-23 University Of South Australia Novel cancer treatment involving modulation of il-3 activity
CN108368167B (zh) * 2015-11-27 2023-09-05 杰特有限公司 Cd131结合蛋白及其应用
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体
WO2023173173A1 (en) * 2022-03-16 2023-09-21 CSL Innovation Pty Ltd Method of treating an eosinophil-associated disease
WO2024081996A1 (en) * 2022-10-20 2024-04-25 CSL Innovation Pty Ltd Method of treating severe asthma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU706462B2 (en) * 1996-01-30 1999-06-17 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists

Also Published As

Publication number Publication date
EP1105426A1 (de) 2001-06-13
EP1105426B1 (de) 2005-05-11
AUPP525198A0 (en) 1998-09-03
EP1105426A4 (de) 2002-03-27
DE69925279D1 (de) 2005-06-16
US7427401B2 (en) 2008-09-23
US6720155B1 (en) 2004-04-13
WO2000009561A1 (en) 2000-02-24
DE69925279T2 (de) 2006-01-26
US20040265957A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
ATE295376T1 (de) Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung
EP0176355A3 (de) Immunologisches Verfahren unabhängig von Antigenen
Voehringer et al. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1)
ATE160379T1 (de) Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
EP2336187B8 (de) Zusammensetzungen und Verfahren von monoklonalen oder polyklonalen Antikörpern, die spezifisch für T-Zell Subpopulationen sind
IT1306704B1 (it) Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
RO115415B1 (ro) Moleculă-3 de adeziune intercelulară (icam-3), moleculă adn recombinant care o codifică, anticorpi ai acesteia, metodă de producere a celulei hibridoma, metode de modulare a funcţiilor biologice, de suprimare, identificare, diagnoză şi compoziţii farmaceutice
BRPI0510079A (pt) anticorpo isolado ou região de ligação de antìgeno do mesmo, célula de hibridoma, célula de transfectoma, anticorpo monoclonal ou região de ligação de antìgeno do mesmo, animal não humano transgênico, método para produzir um anticorpo ou região de ligação de antìgeno do mesmo, composição farmacêutica, uso do anticorpo ou região de ligação de antìgeno, polipeptìdeo isolado, imunoensaio, e, método para identificar um composto
DE69434812D1 (de) Methoden für inhibition der cd14-abhängigen zellaktivierung
DE69417417D1 (de) Monoklonale antikörper gegen den alpha-pdgf-rezeptor und deren verwendungen
DE69230146T2 (de) Monoklonale antikörper gegen putative hcv-e2/ns1-proteine und verfahren zu ihrer verwendung
CY1107858T1 (el) Ccr5 αντισωματα pa14
EP1881064A3 (de) Monoklonale HCV-Kern-Antikörper
CY1110144T1 (el) Αντισωματα για την ταυτοποιηση και/ή την απομονωση τουλαχιστον ενος κυτταρικου πληθυσμου ο οποιος επιλεγεται απο την ομαδα την περιλαμβανουσα αιμοποιητικα βλαστοκυτταρα, νευρικα βλαστοκυτταρα, νευρικα αρχεγονα κυτταρα, μεσεγχυματικα βλαστοκυτταρα και μεσεγχυματικα αρχεγονα κυτταρα
ATE279443T1 (de) A3c6e2, ein monoklonaler antikörper spezifisch für den humanen stammzellfaktor (scf)-rezeptor
WO2002068646A3 (en) Mammalian cytokines; receptors; related reagents and methods
DE69933565D1 (de) Serinprotease-spzifischer moniklonaler antikörper und seine verwendung
ATE217888T1 (de) Monoklonale antikörper gegen leukozyten- spezifische g-protein-gekoppelte rezeptoren
ATE58172T1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
CA2480717A1 (en) Method for producing monoclonal antibodies
Shinjo et al. Monoclonal anti-λ5 antibody FS1 identifies a 130 kDa protein associated with λ5 and Vpre-B on the surface of early pre-B cell lines
AU2003283240A1 (en) Antibody for isolating and/or identifying mesenchymal stem cells and method for isolating and/or identifying mesenchymal stem cells
Baran et al. Characterization of the soluble murine IL-2R and estimation of its affinity for IL-2.
KR930701620A (ko) 재조합 dna 백터를 이용하여 인체 t-세포 리셉터 성분에 대한 단일 클론성 항체의 제조방법
NO962827D0 (no) Monoklonale antistoffer mot antigener uttrykt av hematopoietider facilitatoriske celler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties